Increased serum soluble urokinase-type plasminogen activator receptor (suPAR) Levels in FSGS: A Meta-Analysis

Jiwon M. Lee, Jae Won Yang, Andreas Kronbichler, Michael Eisenhut, Gaeun Kim, Keum Hwa Lee, Jae Il Shin

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Introduction. The soluble urokinase-type plasminogen activator receptor (suPAR) has been found to be elevated in primary focal segmental glomerulosclerosis (pFSGS). However, its usefulness as a biomarker for FSGS remains controversial. We conducted a meta-analysis aiming at investigating the significance of suPAR in diagnosing pFSGS. Methods. Electronic databases (PubMed and EMBASE) were searched to identify studies comparing suPAR levels in FSGS patients and controls, from the earliest available date to May 1, 2018. A random-effects model with standardized mean difference (SMD) was used for meta-analyses. Risk of bias was assessed using the Newcastle-Ottawa quality assessment scale. Results. A total of 187 articles were screened, and the final analysis included 13 articles. In comparison to healthy controls, serum suPAR levels were significantly increased in pFSGS patients (SMD, 1.07, 95% confidence interval (CI) 0.65 to 1.48; participants=814; studies=9, I2=85%). Higher suPAR levels were also found in patients with pFSGS compared to those with minimal change disease (SMD 0.53, 95% CI 0.22 to 0.84). Of note, such a difference was not found in pediatric groups (SMD 0.42, 95% CI -0.13 to 0.96) while it was more evidently noted in adult patients (SMD 1.32, 95% CI 0.90 to 1.74). Serum suPAR levels did not differ between pFSGS patients in remission compared to those in active proteinuric state (SMD 0.29, 95% CI -0.30 to 0.88). Comparison with membranous nephropathy and IgA nephropathy showed no significant difference. Conclusions. Our meta-analysis demonstrated that, in comparison to both healthy controls and controls with minimal change disease, suPAR levels were significantly higher in adult patients with pFSGS. suPAR levels did not differ between pFSGS patients during the initial period of diagnosis and those in remission.

Original languageEnglish
Article number5679518
JournalJournal of immunology research
Volume2019
DOIs
Publication statusPublished - 2019 Jan 1

Fingerprint

Urokinase Plasminogen Activator Receptors
Focal Segmental Glomerulosclerosis
Meta-Analysis
Serum
Confidence Intervals
Lipoid Nephrosis
Membranous Glomerulonephritis
PubMed
Immunoglobulin A
Biomarkers
Databases
Pediatrics

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Immunology

Cite this

Lee, Jiwon M. ; Yang, Jae Won ; Kronbichler, Andreas ; Eisenhut, Michael ; Kim, Gaeun ; Lee, Keum Hwa ; Shin, Jae Il. / Increased serum soluble urokinase-type plasminogen activator receptor (suPAR) Levels in FSGS : A Meta-Analysis. In: Journal of immunology research. 2019 ; Vol. 2019.
@article{db3b377bfc2043b8b72ba71526c3616d,
title = "Increased serum soluble urokinase-type plasminogen activator receptor (suPAR) Levels in FSGS: A Meta-Analysis",
abstract = "Introduction. The soluble urokinase-type plasminogen activator receptor (suPAR) has been found to be elevated in primary focal segmental glomerulosclerosis (pFSGS). However, its usefulness as a biomarker for FSGS remains controversial. We conducted a meta-analysis aiming at investigating the significance of suPAR in diagnosing pFSGS. Methods. Electronic databases (PubMed and EMBASE) were searched to identify studies comparing suPAR levels in FSGS patients and controls, from the earliest available date to May 1, 2018. A random-effects model with standardized mean difference (SMD) was used for meta-analyses. Risk of bias was assessed using the Newcastle-Ottawa quality assessment scale. Results. A total of 187 articles were screened, and the final analysis included 13 articles. In comparison to healthy controls, serum suPAR levels were significantly increased in pFSGS patients (SMD, 1.07, 95{\%} confidence interval (CI) 0.65 to 1.48; participants=814; studies=9, I2=85{\%}). Higher suPAR levels were also found in patients with pFSGS compared to those with minimal change disease (SMD 0.53, 95{\%} CI 0.22 to 0.84). Of note, such a difference was not found in pediatric groups (SMD 0.42, 95{\%} CI -0.13 to 0.96) while it was more evidently noted in adult patients (SMD 1.32, 95{\%} CI 0.90 to 1.74). Serum suPAR levels did not differ between pFSGS patients in remission compared to those in active proteinuric state (SMD 0.29, 95{\%} CI -0.30 to 0.88). Comparison with membranous nephropathy and IgA nephropathy showed no significant difference. Conclusions. Our meta-analysis demonstrated that, in comparison to both healthy controls and controls with minimal change disease, suPAR levels were significantly higher in adult patients with pFSGS. suPAR levels did not differ between pFSGS patients during the initial period of diagnosis and those in remission.",
author = "Lee, {Jiwon M.} and Yang, {Jae Won} and Andreas Kronbichler and Michael Eisenhut and Gaeun Kim and Lee, {Keum Hwa} and Shin, {Jae Il}",
year = "2019",
month = "1",
day = "1",
doi = "10.1155/2019/5679518",
language = "English",
volume = "2019",
journal = "Journal of Immunology Research",
issn = "2314-8861",
publisher = "Hindawi Publishing Corporation",

}

Increased serum soluble urokinase-type plasminogen activator receptor (suPAR) Levels in FSGS : A Meta-Analysis. / Lee, Jiwon M.; Yang, Jae Won; Kronbichler, Andreas; Eisenhut, Michael; Kim, Gaeun; Lee, Keum Hwa; Shin, Jae Il.

In: Journal of immunology research, Vol. 2019, 5679518, 01.01.2019.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Increased serum soluble urokinase-type plasminogen activator receptor (suPAR) Levels in FSGS

T2 - A Meta-Analysis

AU - Lee, Jiwon M.

AU - Yang, Jae Won

AU - Kronbichler, Andreas

AU - Eisenhut, Michael

AU - Kim, Gaeun

AU - Lee, Keum Hwa

AU - Shin, Jae Il

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Introduction. The soluble urokinase-type plasminogen activator receptor (suPAR) has been found to be elevated in primary focal segmental glomerulosclerosis (pFSGS). However, its usefulness as a biomarker for FSGS remains controversial. We conducted a meta-analysis aiming at investigating the significance of suPAR in diagnosing pFSGS. Methods. Electronic databases (PubMed and EMBASE) were searched to identify studies comparing suPAR levels in FSGS patients and controls, from the earliest available date to May 1, 2018. A random-effects model with standardized mean difference (SMD) was used for meta-analyses. Risk of bias was assessed using the Newcastle-Ottawa quality assessment scale. Results. A total of 187 articles were screened, and the final analysis included 13 articles. In comparison to healthy controls, serum suPAR levels were significantly increased in pFSGS patients (SMD, 1.07, 95% confidence interval (CI) 0.65 to 1.48; participants=814; studies=9, I2=85%). Higher suPAR levels were also found in patients with pFSGS compared to those with minimal change disease (SMD 0.53, 95% CI 0.22 to 0.84). Of note, such a difference was not found in pediatric groups (SMD 0.42, 95% CI -0.13 to 0.96) while it was more evidently noted in adult patients (SMD 1.32, 95% CI 0.90 to 1.74). Serum suPAR levels did not differ between pFSGS patients in remission compared to those in active proteinuric state (SMD 0.29, 95% CI -0.30 to 0.88). Comparison with membranous nephropathy and IgA nephropathy showed no significant difference. Conclusions. Our meta-analysis demonstrated that, in comparison to both healthy controls and controls with minimal change disease, suPAR levels were significantly higher in adult patients with pFSGS. suPAR levels did not differ between pFSGS patients during the initial period of diagnosis and those in remission.

AB - Introduction. The soluble urokinase-type plasminogen activator receptor (suPAR) has been found to be elevated in primary focal segmental glomerulosclerosis (pFSGS). However, its usefulness as a biomarker for FSGS remains controversial. We conducted a meta-analysis aiming at investigating the significance of suPAR in diagnosing pFSGS. Methods. Electronic databases (PubMed and EMBASE) were searched to identify studies comparing suPAR levels in FSGS patients and controls, from the earliest available date to May 1, 2018. A random-effects model with standardized mean difference (SMD) was used for meta-analyses. Risk of bias was assessed using the Newcastle-Ottawa quality assessment scale. Results. A total of 187 articles were screened, and the final analysis included 13 articles. In comparison to healthy controls, serum suPAR levels were significantly increased in pFSGS patients (SMD, 1.07, 95% confidence interval (CI) 0.65 to 1.48; participants=814; studies=9, I2=85%). Higher suPAR levels were also found in patients with pFSGS compared to those with minimal change disease (SMD 0.53, 95% CI 0.22 to 0.84). Of note, such a difference was not found in pediatric groups (SMD 0.42, 95% CI -0.13 to 0.96) while it was more evidently noted in adult patients (SMD 1.32, 95% CI 0.90 to 1.74). Serum suPAR levels did not differ between pFSGS patients in remission compared to those in active proteinuric state (SMD 0.29, 95% CI -0.30 to 0.88). Comparison with membranous nephropathy and IgA nephropathy showed no significant difference. Conclusions. Our meta-analysis demonstrated that, in comparison to both healthy controls and controls with minimal change disease, suPAR levels were significantly higher in adult patients with pFSGS. suPAR levels did not differ between pFSGS patients during the initial period of diagnosis and those in remission.

UR - http://www.scopus.com/inward/record.url?scp=85065803630&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85065803630&partnerID=8YFLogxK

U2 - 10.1155/2019/5679518

DO - 10.1155/2019/5679518

M3 - Article

C2 - 31089477

AN - SCOPUS:85065803630

VL - 2019

JO - Journal of Immunology Research

JF - Journal of Immunology Research

SN - 2314-8861

M1 - 5679518

ER -